Dr. Mohty thanks Professor J.V. de Melo (Adelaide, South Australia, Australia) for critical reading of the article. We also thank the “Association pour la Recherche sur le Cancer (ARC),” the “Fondation de France,” the “Fondation contre la Leucémie,” the “Agence de Biomédecine,” the “Association Cent pour Sang la Vie,” the “Association Laurette Fuguain,” the “IRGHET” and the “Ligue contre le Cancer (Comités Départementaux de l'Inter-région Grand-Ouest Bretagne, Centre, Pays-de-Loire, Poitou-Charentes)” for their generous and continuous support for our clinical and basic research work.
The effects of bortezomib on bone disease in patients with multiple myeloma
Article first published online: 18 NOV 2013
© 2013 American Cancer Society
Volume 120, Issue 5, pages 618–623, 1 March 2014
How to Cite
Mohty, M., Malard, F., Mohty, B., Savani, B., Moreau, P. and Terpos, E. (2014), The effects of bortezomib on bone disease in patients with multiple myeloma. Cancer, 120: 618–623. doi: 10.1002/cncr.28481
- Issue published online: 19 FEB 2014
- Article first published online: 18 NOV 2013
- Manuscript Accepted: 21 OCT 2013
- Manuscript Revised: 15 SEP 2013
- Manuscript Received: 16 JUL 2013
- multiple myeloma;
- bone remodeling;
- tumor microenvironment
Bortezomib has demonstrated substantial activity in the treatment of patients with multiple myeloma and is widely incorporated into treatment strategies across the different settings. It is interesting to note that data are accumulating to suggest that the activity of bortezomib extends beyond the tumor cell and microenvironment to encompass effects on bone metabolism. Indeed, data from both the preclinical and clinical settings have suggested that bortezomib directly stimulates osteoblast growth and differentiation, while also inhibiting osteoclast development and activity. Notably, in the clinical setting, the bone anabolic effects of bortezomib could be demonstrated by the healing of lytic lesions as noted in some patients. These results are of importance because bone disease is a hallmark of myeloma and therefore any agent that combines antimyeloma activity with positive effects on bone is of substantial interest. However, further studies are needed to establish how the agent should be used for the treatment of patients with bone disease. Cancer 2014;120:618–623. © 2013 American Cancer Society.